Development
Ekso Bionics Holdings, Inc.
EKSO
$3.14
-$0.11-3.39%
NASDAQ
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 5.21% | -2.04% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.21% | -2.04% | |||
| Cost of Revenue | 15.20% | -12.17% | |||
| Gross Profit | -3.54% | 8.96% | |||
| SG&A Expenses | 19.51% | -17.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.06% | -16.12% | |||
| Operating Income | -17.67% | 31.58% | |||
| Income Before Tax | 4.49% | 20.45% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 4.49% | 20.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.49% | 20.45% | |||
| EBIT | -17.67% | 31.58% | |||
| EBITDA | -7.15% | 35.55% | |||
| EPS Basic | 6.94% | 22.92% | |||
| Normalized Basic EPS | 6.89% | 22.95% | |||
| EPS Diluted | 5.35% | 22.92% | |||
| Normalized Diluted EPS | 6.89% | 22.95% | |||
| Average Basic Shares Outstanding | 2.65% | 3.20% | |||
| Average Diluted Shares Outstanding | 2.65% | 3.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||